Coinbase CEO Brian Armstrong has ventured into the world of biotech, supporting a company aiming to reverse the effects of aging. Through his startup, NewLimit, they’re developing treatments that could significantly extend healthy lifespans, attracting significant investment from prominent venture capitalists. NewLimit, founded by Brian Armstrong, former GV partner Blake Bryers, and stem cell professor Jacob Kimmel, is at the forefront of genetic reprogramming, aiming to rejuvenate aged cells and restore their youthful functionality. This innovative approach has attracted attention from a wide range of investors including Kleiner Perkins, Nat Friedman, Daniel Gross, Khosla Ventures, Founders Fund, Dimension Capital, Elad Gil, and Patrick Collison. Recent funding of $130 million in a Series B round underscores NewLimit’s progress and commitment to this ambitious goal, following a successful $40 million Series A two years prior. This investment highlights the growing interest in extending human lifespan through biotech advancements.